Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer

Front Oncol. 2022 Nov 17:12:1084708. doi: 10.3389/fonc.2022.1084708. eCollection 2022.

Authors

Cynthia Ménard¹, Inmaculada Navarro-Domenech², Zhihu Amy Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², Peter Chung²

Affiliations

¹ Radiation Oncology, Centre Hospitaliser de l'Université de Montréal (CHUM), Montreal, QC, Canada.
² Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
³ Radiation Oncology, Polytechnique Montreal, Montreal, QC, Canada.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.971344.].

Keywords: brachytherapy; magnetic resonance imaging; prostate cancer; radiotherapy; salvage.

Copyright © 2022 Ménard, Navarro-Domenech, Liu, Joseph, Barkati, Berlin, Delouya, Taussky, Beauchemin, Nicolas, Kadoury, Rink, Raman, Sundaramurthy, Weersink, Beliveau-Nadeau, Helou and Chung.

Publication types

Published Erratum